Abstract: Described is a ultrasonic welding of laminates, more particular to the use of ultrasonic energy to create stable perforations in a laminate, in particular a laminate that includes a silicone gel. Specifically, a perforation element is provided, that is optionally part of array of perforation elements, which perforation element or array of perforation elements is advantageously used in an ultrasonic welding device and in a process for continuously introducing perforations into a laminate.

Abstract: A method for manufacturing a wound dressing having a substrate, and a wound dressing manufactured by such a method are described. The method has a step of providing a sacrificial layer of material to be perforated by means of a hot pin perforator, in order to remove any molten residues on the heated pins of the hot pin perforator, before the same pins are used to make holes in the substrate. The presented method is cost effective, robust and reduces the risk of contaminating substances being embedded in the substrate during the hole making process.

Abstract: Described is a ultrasonic welding of laminates, more particular to the use of ultrasonic energy to create stable perforations in a laminate, in particular a laminate that includes a silicone gel. Specifically, a perforation element is provided, that is optionally part of array of perforation elements, which perforation element or array of perforation elements is advantageously used in an ultrasonic welding device and in a process for continuously introducing perforations into a laminate.

Abstract: Infant formula containing osteopontin and use of osteopontin as supplement for infant formulas or baby food.

Abstract: A method for manufacturing a wound dressing having a substrate, and a wound dressing manufactured by such a method are described. The method has a step of providing a sacrificial layer of material to be perforated by means of a hot pin perforator, in order to remove any molten residues on the heated pins of the hot pin perforator, before the same pins are used to make holes in the substrate. The presented method is cost effective, robust and reduces the risk of contaminating substances being embedded in the substrate during the hole making process.

Abstract: A concentrate derived from milk or a milk product comprising sialyllactose in amounts higher than the normal amounts found in the milk or milk product and a process for preparation of such a concentrate by ultrafiltration and diafiltration using a thin film polyamide based membrane. The concentrate is suited for use in nutritional products.

Abstract: Infant formula containing osteopontin and use of osteopontin as supplement for infant formulas or baby food.

Abstract: A concentrate derived from milk or a milk product comprising sialyllactose in amounts higher than the normal amounts found in the milk or milk product and a process for preparation of such a concentrate by ultrafiltration and diafiltration using a thin film polyamide based membrane. The concentrate is suited for use in nutritional products.

Abstract: A concentrate derived from milk or a milk product comprising sialyllactose in amounts higher than the normal amounts found in the milk or milk product and a process for preparation of such a concentrate by ultrafiltration and diafiltration using a thin film polyamide based membrane. The concentrate is suited for use in nutritional products.

Abstract: Use of osteopontin for reducing plaque bacterial growth on tooth enamel and dental formulations containing osteopontin.

Abstract: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

Abstract: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11?-hydroxy-steroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

Abstract: Infant formula containing osteopontin and use of osteopontin as supplement for infant formulas or baby food.

Abstract: Use of osteopontin for reducing plaque bacterial growth on tooth enamel and dental formulations containing osteopontin.

Abstract: The use of substituted amides for modulating the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Abstract: The present invention relates to a method for constructing a host cell expressing a polypeptide of interest from at least two ORF's stably integrated onto the chromosome of the host cell comprising the steps of: a) providing the at least two ORF's encoding the same polypeptide, wherein the at least two DNA sequences of the ORF's differ in at least one position; b) integrating the at least two ORF's in the same orientation on the host cell chromosome.

Abstract: The present invention provides improved methods of producing S2A (or S1E) proteases in Gram-positive expression host cells, the method comprising the steps of (a) cultivating in a fed-batch fermentation a Gram-positive cell comprising at least one polynucleotide encoding the heterologous S2A/S1E protease under conditions conducive for production of the protease, wherein at least 20% of the duration of said cultivating takes place at a temperature of below 36.5OC; and (b) recovering the protease.

Abstract: A Bacillus licheniformis mutant host cell derived from a parent B. licheniformis host cell, which mutant host cell is mutated in one or more gene(s) encoding one or more polypeptide(s) involved in sporulation which is at least 80% identical to one or more of the polypeptides shown in SEQ ID NO's: 2 to 191, wherein the mutant host cell expresses at least 5% less of the one or more polypeptide(s) involved in sporulation than the parent host cell, when they are cultivated under comparable conditions.

Abstract: A Bacillus licheniformis mutant host cell derived from a parent B. licheniformis host cell, which mutant host cell is mutated in one or more gene(s) encoding one or more polypeptide(s) involved in antibiotic synthesis which is at least 80% identical to one or more of the polypeptides shown in SEQ ID NO's: 2 to 22, wherein the mutant host cell expresses at least 5% less of the one or more polypeptide(s) involved in antibiotic synthesis than the parent host cell, when they are cultivated under comparable conditions.

Abstract: A Bacillus licheniformis mutant host cell derived from a parent B. licheniformis host cell, which mutant host cell is mutated in one or more gene(s) encoding one or more secreted polypeptide(s) which is at least 80% identical to one or more of the polypeptides shown in SEQ ID NO's: 2 to 248, wherein the mutant host cell secretes at least 5% less of the one or more secreted polypeptide(s) than the parent host cell, when they are cultivated under comparable conditions.